Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Novartis Ag

Rheinisch-westfaelische Technische Hochschule Aachen

Rheinisch-westfalische Technische Hochschule Aachen

Mehmet Kemal Tur

Stefan Barth

Rainer Fischer

Michael Otto Bardroff

Matthew John Edwards

Ahmad Fawzi Hussain

Michael Stöcker

Olaf Ratsch

Michael Huhn

Jenny Fitting

Matthew Edwards

Theo Thepen

A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.

Fusion protein to target and treat acute myeloid leukemia cells

Photoimmunoconjugates for use in photodynamic therapy

A synthetic, soluble, endogenous complex formed from at least one component A and at least one component B, whereby component A comprises a binding domain for extra-cellular surface structures that internalize upon binding of component A of said complex, and component B has a constitutive catalytic kinase activity and effects cell biosynthesis/signalling including cell death after internalization. The complex allows to influence the growth and the physiology of cells. In particular said complex, nucleic acid molecules encoding it, cells transfected or transformed with these nucleic acid molecules are usable for the preparation of medicaments for the treatment of proliferative diseases, inflammatory diseases, allergies and autoimmune diseases.

Immunokinases

The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease, and Hodgkin's lymphoma.

Organic compounds

Growing community of inventors

Giessen, Germany

Mehmet Kemal Tur